首页>投融资
Oragenics
增发
Oragenics, Inc.(前身为oragen股份有限公司)成立于1996年11月,但是经营活动直到1999年才开始。公司的专注于发现、发展、商业化一系列有关口腔健康、广谱抗生素和其他健康技术的好处。 Oragenics股份有限公司作为一家医疗保健公司,专注于开发新的抗生素和口腔保健产品。公司向消费者和牙科专业人士销售利于口腔健康的混合益生菌产品:probiora3。该公司还拥有一套在口腔健康领域研究数年得到的专利技术。
基本信息
-
公司全称Oragenics Inc
-
类型疫苗研发商
-
产业领域生物药
-
公司人数15人以下
-
地址4902 Eisenhower Blvd. Suite 125 Tampa FL 33634
-
联系电话1-813-2867900
-
邮箱info@oragenics.com
-
成立时间1996-01-01
投融资
-
2024-03-01增发210万美元未透露
-
2023-08-08上市后再融资117万美元未透露
-
2023-06-05上市后再融资未透露CQDM
-
2019-03-25增发1250万美元未透露
-
2018-07-17增发1380万美元未透露
-
2018-04-11上市后再融资180万美元未透露
-
2017-11-09上市后再融资330万美元未透露
-
2017-07-26未透露300万美元未透露
-
2016-07-13未透露470万美元未透露
-
2015-10-15未透露990万美元未透露
-
2013-04-10上市未透露未透露
-
2012-08-10未透露250万美元未透露
-
2012-06-15未透露580万美元未透露
-
2012-03-23未透露1120万美元未透露
-
2010-08-11未透露200万美元未透露
- 加载更多
相关投融资企业
A+轮
ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians University of Munich. ViGeneron dedicated to develop innovative gene therapies based on our two unique and proprietary technology platformsIn November 2019, the company announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China
上市
Anteris Technologies Ltd (formerly known as Admedus (formerly known as Allied Healthcare Group Ltd), through its subsidiary Admedus Vaccines (formerly Coridon)), is a structural heart company delivering clinically superior solutions, focused on the development of next-generation technologies with world class partners.In July 2010, Australian medical devices company, Allied Medical, planned to acquire a 38.6% controlling stake in Coridon via a AUD $3 million (US $2.6 million) rights issue. Under the agreement, Allied Medical could acquire up to 55.7% interest. In June 2011 BioMD and Allied Medical Ltd were merged to form Allied Healthcare Group. In April 2012, Allied Healthcare held a 44% stake in Coridon. In July 2013, Allied Healthcare increased the stake in Coridon from 44 to 50.1%.In February 2023, Anteris Technologies Ltd completed equity fundraising, as a result of which the company issued 1.458 million new ordinary shares at an issue price of $24.00
A轮
Atb Therapeutics is a developer of monoclonal antibodies from plant cells designed to treat cancer